Clinical Trial Update: Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" [Phase 2]

View source ↗

Summary

An ongoing Phase 2 trial is evaluating Daratumumab (Darzalex) for residual disease in T-cell acute lymphoblastic leukemia, with recruiting status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Sponsor: Tata Memorial Centre | Conditions: T Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING